Haidilao's comment is different from Jiumaojiu (9922.HK), which noted sequential improvement in April and Labor Day holiday (see our China BEST Conference takeaways for JMJ here). May 9, 2025 02:04 PM GMT Haidilao International Holding Ltd | Asia Pacific M Update China BEST Conference 2025 Feedback Key Takeaways Potential reasons behind the table turn weakness: Morgan Stanley Asia Limited+ Hildy.Ling@morganstanley.com +852 2239-7834 Cindy Gao Research Associate Cindy.XY.Gao@morganstanley.com +852 3963-0149 ...

Core Viewpoint - Tethys Petroleum Limited reported significant declines in financial performance for the year ended December 31, 2024, primarily due to lower oil and gas sales and production challenges [2][3]. Financial Performance - Oil and gas sales decreased by 58% to $15.2 million in 2024 from $36.5 million in 2023 [2]. - The net loss for 2024 was $19.1 million, compared to a profit of $9.7 million in 2023 [2]. - The results were negatively impacted by non-cash charges, including an impairment of Kul-Bas contract area costs and currency translation differences due to the depreciation of the Kazakhstan tenge against the US dollar [2]. Management Outlook - Management remains confident about Tethys's future despite production license approval delays and declining oil and gas prices [3]. - The company has little to no debt and possesses valuable operating assets, which positions it favorably for future development [3]. - Challenges in developing oil handling, gas utilization, and logistics are acknowledged, but management believes these can be addressed over time [3]. Company Overview - Tethys is focused on oil and gas exploration and production in Central Asia and the Caspian Region, with significant potential in both exploration and discovered deposits [4].

Aldeyra Therapeutics (ALDX) FY 2025 Conference February 11, 2025 09:20 AM ET Company Participants Todd Brady - CEO, President & Director Conference Call Participants François Brisebois - Managing Director, Senior Biotechnology Research Analyst François Brisebois Alright. Great. Thank you for joining. My name is Frank Breasbois. I'm one of the biotech analysts at Oppenheimer. Our next presenting company here is Aldara Therapeutics. From the company, we have CEO, Todd Brady, to join. I think what we're going ...